Yubo International Biotech Ltd. (YBGJ)

[Potse]

S-1/A items/observations, VIV-CELL store opening......

1) Based on some of the numbers/info in the paragraphs below, I think Q2 will probably continue to be low. Some quick/rough back-of-the-envelope calculations is leading me to believe it will probably be somewhere above $300K........

Respiratory atomization products (nebulizers): include lung regulating essence, which is applied through an atomizer and formulated on the basis of multiple growth factors rich in the polypeptide of cell technology such as FGF, EGF, VEGF, etc. to repair and cure the lungs. Our products can enhance the regeneration of lung stem cells, inhibit apoptosis of normal lung cells, improve immunity, relieve dry and astringent foreign body sensation, and relieve chest tightness, chest pain, wheezing, breathing difficulties and other symptoms. We launched our respiratory atomization products in April 2020 and the sales of these products have accumulated to approximately $1.7 million since launch. Our respiratory atomization products are sold in Guangdong, Shandong, Hebei, Henan, Chongqing and Sichuan provinces. The customer base for these products mainly includes middle class and above population with respiratory system diseases or weaknesses, or low immunity.

Cell basidiomycetes compound drink/beverage: This product is registered as beverage. Based on cellular immunology, combined with traditional Chinese medicine theories and natural plant extracts such as basidiomycetes, red ginseng and polygonatum, it has the benefits of rapid activation of immune cells, regulation of immune system, anti-tumor, anti-virus, hypoglycemic and anti-oxidation. We launched our cell basidiomycetes compound drink in February 2021 and the sales of this product have accumulated to approximately $400,000 by end of May 2021. We are still in the process of promoting this product to cover more regional markets. The customer base for this drink mainly includes middle class and above population who are recovering from major epidemic diseases or with low immunity.

2) YBGJ is expecting a tripling of its employee count in 2022......

We currently employ 20 employees at our headquarters, located at Room 105, Building 5, 31 Xishiku Avenue, Xicheng District, Beijing, PRC. Our employees include three executive officers, two financial department personnel, two administrative management personnel, six R&D and product personnel, six planning and marketing personnel, and one person in IT management. With the expansion of our business and establishment of our stem cell bank in Chengdu, China, we plan to increase our recruitment efforts in the fields of technology, research and development and marketing, and we expect to employ approximately 60 employees in 2022. In order to attract, retain and reward top talents in the industry, we are considering establishing various incentive program for our employees, and we may establish an equity incentive plan in the future.

3) Cheung Ho Shun, who invested $750K at the equivalent of 43 cents prior to YBGJ going public, loaned YBGJ $600K in May......

On May 11, 2021, we entered into a verbal loan agreement with World Precision Medicine Technology Inc., a company owned and controlled by Cheung Ho Shun, one of our existing shareholders, which provided the Company with a working capital loan in the principal amount of $600,000. The loan is due on demand and non-interest bearing.

4) There was an opening ceremony for another VIV-CELL store last week.....

On the morning of July 25, 2021, the opening ceremony of VIV-CELL Yubo Biotechnology Experience Center was grandly held in Qingdao Belle Plaza.

https://mp.weixin.qq.com/s?src=11×tamp=1628172312&ver=3234&signature=TH2gtL6SvuKznjK0gqLj3A9O3U3Dc*5b2bG3dNZ*zIkSazDEgR04xw1PUkrbBhGmXCNANDMBaEWsA3aqZhbB59uDleOcMWpr3YJXEy2VyDGh5lWZ403V7QUdiWCIg2-S&new=1